β³ Fetching live dividend data...
Home βΊ Calculator βΊ OCUP Dividend Calculator 2026
Ocuphire Pharma, Inc. Β· NASDAQ
Price: $1.17 Β· Annual div: $2.00/share Β· Frequency: quarterly Β· Payout ratio: 50% Β· Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in OCUP β $213.17M in 10 years Β· $11,207,880.51/month
Ocuphire Pharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to researching and bringing to market treatments for various refractive and retinal eye conditions. The company's primary investigational drug is Nyxol eye drops, a preservative-free phentolamine mesylate formulation administered once daily. Nyxol is currently undergoing advanced (Phase III) clinical trials for individuals experiencing difficulties with dim light or night vision. It is also in Phase 2b testing for reversing pharmacologically induced pupil dilation, and has successfully completed its Phase 2 VEGA-1 study for the treatment of presbyopia (age-related farsightedness). Beyond Nyxol, Ocuphire is developing APX3330, an oral tablet taken twice a day. This medication is designed to address key pathways involved in vascular diseases affecting the retina and choroid, including conditions like diabetic retinopathy and diabetic macular edema. Furthermore, the company is exploring APX2009 and APX2014, which are next-generation preclinical drug candidates and analogs derived from APX3330. Ocuphire Pharma, Inc. is based in Farmington Hills, Michigan.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open OCUP position with:
Real after-tax yield depends on where you live and how you hold OCUP.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 170.94% | 168.14% | $17,094 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 145.30% | 142.50% | $14,530 / yr |
| πΊπΈ US Taxable (20%) | 20% | 136.75% | 133.95% | $13,675 / yr |
| π¬π§ UK ISA | 0% | 170.94% | 168.14% | $17,094 / yr |
| π¬π§ UK Taxable | 8.75% | 155.98% | 153.18% | $15,598 / yr |
| π¨π¦ TFSA | 0% | 170.94% | 168.14% | $17,094 / yr |
| π¨π¦ CA Taxable | 25% | 128.20% | 125.40% | $12,821 / yr |
| π¦πΊ Super (pension) | 15% | 145.30% | 142.50% | $14,530 / yr |
| π¦πΊ AU Taxable | 30% | 119.66% | 116.86% | $11,966 / yr |
| π©πͺ DE Taxable | 26.375% | 125.85% | 123.05% | $12,585 / yr |
| π«π· FR Taxable | 30% | 119.66% | 116.86% | $11,966 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
OCUP pays quarterly β 4 times per year. Next ex-div: TBD.
How OCUP compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for OCUP sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2024-06-11 | 41,143 | β | β | ||
| A-Award | 2024-06-11 | 35,181 | $1.72 | $60.5K | ||
| A-Award | 2024-06-11 | 41,143 | β | β | ||
| A-Award | 2024-06-11 | 35,181 | $1.72 | $60.5K | ||
| A-Award | 2024-06-11 | 41,143 | β | β | ||
| A-Award | 2024-06-11 | 35,181 | $1.72 | $60.5K | ||
| A-Award | 2024-06-11 | 41,143 | β | β | ||
| A-Award | 2024-06-11 | 35,181 | $1.72 | $60.5K | ||
| A-Award | 2024-06-11 | 41,143 | β | β | ||
| A-Award | 2024-06-11 | 35,181 | $1.72 | $60.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the OCUP dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Ocuphire Pharma, Inc. (OCUP) is currently trading at $1.17, trading near its 52-week low. The current dividend yield is 170.94% based on an annual payout of $2.00 per share.
Ocuphire Pharma, Inc. (OCUP) is a healthcare stock currently trading at $1.17 with a dividend yield of 170.94%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only β not financial advice.
Real users. No sign-up required to leave a review.
βFinally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.β
βI've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly β $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.β
βReally solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.β
βAs someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.β
βThe Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.β
Reviews reflect users' personal experiences. Not financial advice.
Leave a review β